Is insulin glargine (Lantus) safe to use during pregnancy, and should I continue it if I am already pregnant and using it?

Lantus (Insulin Glargine) in Pregnancy

If you are already pregnant and successfully using Lantus (insulin glargine), you should continue it throughout pregnancy. 1

Key Recommendation

The Endocrine Society Clinical Practice Guideline (2013) explicitly states: "We suggest that women with diabetes successfully using the long-acting insulin analogs insulin detemir or insulin glargine preconceptionally may continue with this therapy before and then during pregnancy." 1

This is a Grade 2 recommendation with moderate quality evidence, meaning the benefits clearly outweigh any theoretical risks.

Important Context and Nuances

FDA Status vs Clinical Reality

• Insulin glargine is NOT FDA-approved for pregnancy (Category C), while insulin detemir IS FDA-approved 1
• However, both are widely used in pregnancy with evidence of safety 1
• The lack of FDA approval reflects absence of controlled trials in pregnant women, not evidence of harm 2

What You Need to Know

If already on Lantus before pregnancy:

• Continue it if you have good glycemic control 1
• The risk of changing insulin regimens and destabilizing glucose control outweighs theoretical concerns 3
• Switching medications during pregnancy can worsen maternal blood sugar levels, which poses greater fetal risk than continuing glargine 3

Preconception counseling should include:

• Discussion of glargine's lack of FDA approval 1
• Discussion of theoretical mitogenicity concerns (which have not materialized in clinical practice) 1
• Option to switch to insulin detemir or NPH insulin if preferred 1

Safety Evidence

Multiple studies support glargine's safety:

• No increased adverse maternal or neonatal outcomes compared to NPH insulin 4, 5, 6
• Minimal to negligible placental transfer at therapeutic concentrations 4, 6
• Meta-analysis of 702 pregnancies showed no significant differences in fetal outcomes (macrosomia, neonatal hypoglycemia, congenital anomalies, preterm delivery) between glargine and NPH 7, 5
• Lower rates of nocturnal hypoglycemia compared to NPH insulin 1

Clinical Advantages of Continuing Glargine

• Maintains established glycemic control without the disruption of switching regimens
• Reduces nocturnal hypoglycemia risk compared to NPH insulin 1
• Provides 24-hour basal coverage with once-daily dosing
• Patient familiarity with dosing and adjustment reduces errors

Practical Management Algorithm

For women already on glargine:

1. Continue current dose initially
2. Monitor glucose closely (preprandial target ≤95 mg/dL, 1-hour postprandial ≤140 mg/dL, or 2-hour postprandial ≤120 mg/dL) 1
3. Expect insulin requirements to:
   • Decrease in first trimester
   • Increase in second and third trimesters
   • Rapidly decline after delivery 2
4. Adjust doses based on frequent glucose monitoring

For women not yet on insulin:

• Insulin detemir may be preferred as first-line long-acting analog (FDA-approved) 1
• NPH insulin remains an acceptable alternative 1
• Glargine can be initiated if detemir or NPH result in problematic hypoglycemia 1

Common Pitfalls to Avoid

1. Don't automatically switch from glargine to another insulin if glycemic control is good—this creates unnecessary risk of destabilization
2. Don't underdose insulin out of fear—hyperglycemia poses greater fetal risk than the insulin itself
3. Don't forget to adjust doses as pregnancy progresses—requirements change dramatically across trimesters
4. Don't discontinue monitoring postpartum—insulin sensitivity increases dramatically after delivery, requiring dose reduction to prevent hypoglycemia 2

Additional Pregnancy Considerations

• Combine with rapid-acting insulin analogs (aspart or lispro, NOT glulisine) for prandial coverage 1
• Start folic acid 5 mg daily if planning pregnancy 1
• Ensure ophthalmology evaluation before conception and each trimester if retinopathy present 1
• Target HbA1c as close to normal as safely achievable without hypoglycemia 1

The bottom line: Lantus can be safely continued during pregnancy in women already using it successfully, with the primary focus being optimal glucose control to minimize maternal and fetal complications.